glp-1 receptor agonists in pediatric and adolescent obesity prescribing among teens with GLP-1 Receptor Agonists and Research

Description

Note: This article offers general information and does not replace professional medical advice

A number of studies dedicated to GLP-1RA efficacy in T2D included patients with chronic HF (CHF) (16.2% in the EXSCEL trial, 23.6% in SUSTAIN-6, 12.2% in PIONEER, 8.6% in REWIND, 20% in Harmony, 22% in ELIXA and 18% in LEADER)

The prospect of having a new medication to treat multiple chronic conditions is exciting, but more research is still needed

GLP-1 receptor agonists have been shown in multiple studies to exert anti-inflammatory effects, including inhibition of monocyte chemotaxis, suppression of macrophage inflammatory responses, and AMPK-mediated downregulation of the NF-B signaling pathway, thereby reducing systemic inflammation (36)